<p>加拿大温哥華，2026 年 1 月 14 日（GLOBE NEWSWIRE）——Clearmind Medicine Inc.（納斯達克：CMND），（法蘭克福證券交易所：CWY0）（“Clearmind” 或 “公司”）是一家臨牀階段的生物技術公司，專注於發現和開發新型神經可塑素衍生的治療藥物，以解決主要的未得到充分治療的健康問題。今天，公司宣佈其正在進行的 FDA 批准的 I/IIa 期臨牀試驗的第二組所有患者的治療已成功完成，該試驗評估了 CMND-100，即公司自主研發的基於 MEAI 的口服藥物候選者，用於治療酒精使用障礙（AUD）。</p>
<p>第二組由六名患者組成，這些患者來自包括約翰霍普金斯大學、特拉維夫索拉斯基醫療中心和哈達薩醫療中心在內的頂級臨牀機構，現已按照協議完全完成治療。這個里程碑建立在第一組的積極結果之上，第一組顯示出良好的安全性特徵和初步的療效信號，包括減少渴求和戒斷症狀。</p>
<p>“我們很高興地宣佈第二組的治療成功完成，這在獲得 DSMB 批准繼續招募後一個月內實現，標誌着我們跨國 I/IIa 期試驗的持續穩定進展，” Clearmind Medicine 首席執行官 Adi Zuloff-Shani 博士表示。“這一成就反映了我們臨牀機構的奉獻精神以及對 CMND-100 作為 AUD 潛在創新療法的強烈興趣，這是一種具有顯著未滿足醫療需求的疾病。我們期待即將發佈的數據，並向後續組別推進。”</p>
<p>I/IIa 期試驗是一項跨國、多中心研究，旨在評估 CMND-100 在中度至重度 AUD 患者中的安全性、耐受性、藥代動力學和初步療效。第二組的頂線結果預計將在未來幾個月內公佈。</p>
<p><strong>關於 Clearmind Medicine Inc.</strong></p>
<p>Clearmind 是一家臨牀階段的迷幻藥物生物技術公司，專注於發現和開發新型迷幻藥衍生的治療藥物，以解決廣泛且未得到充分服務的健康問題，包括酒精使用障礙。其主要目標是研究和開發基於迷幻藥的化合物，並嘗試將其商業化為受監管的藥物、食品或補充劑。</p>
<p>公司的知識產權組合目前包括十九個專利系列，其中包括 31 項已授予的專利。公司打算在必要時為其化合物申請更多專利，並將保持機會主義，收購更多知識產權以擴展其組合。</p>
<p>Clearmind 的股票在納斯達克以 “CMND” 符號交易，在法蘭克福證券交易所以 “CWY0” 符號交易。</p>
<p>欲瞭解更多信息，請訪問：https://www.clearmindmedicine.com 或聯繫：</p>
<p>投資者關係</p>
<p>invest@clearmindmedicine.com</p>
<p>電話：（604）260-1566</p>
<p>美國：CMND@crescendo-ir.com</p>
<p>一般諮詢</p>
<p>Info@Clearmindmedicine.com</p>
<p>www.Clearmindmedicine.com</p>
<p><strong>前瞻性聲明：</strong></p>
<p>本新聞稿包含《私人證券訴訟改革法案》和其他證券法意義上的 “前瞻性聲明”。諸如 “預計”、“預期”、“打算”、“計劃”、“相信”、“尋求”、“估計” 等詞語或類似表達或變體旨在識別前瞻性聲明。例如，公司在討論我們跨國 I/IIa 期試驗的進展、對 CMND-100 作為 AUD 潛在創新療法的興趣以及向後續組別推進時使用了前瞻性聲明。前瞻性聲明不是歷史事實，基於管理層當前的期望、信念和預測，許多預測本質上是不確定的。這些期望、信念和預測是以誠信表達的。然而，無法保證管理層的期望、信念和預測將會實現，實際結果可能與前瞻性聲明中所表達或暗示的結果有重大差異。前瞻性聲明受到風險和不確定性的影響，這可能導致實際表現或結果與前瞻性聲明中所表達的有重大差異。有關影響公司的風險和不確定性的更詳細描述，請參考公司不時向證券交易委員會（“SEC”）提交的報告，包括但不限於公司截至 2024 年 10 月 31 日的財政年度的 20-F 表格年報中詳細列出的風險。前瞻性聲明僅在聲明發布之日有效。公司不承擔更新前瞻性聲明以反映實際結果、後續事件或情況、假設變化或影響前瞻性信息的其他因素的義務，除非適用的證券法要求。如果公司更新一項或多項前瞻性聲明，不應推斷公司將就此或其他前瞻性聲明進行額外更新。提供的參考和鏈接到網站僅為方便，網站上包含的信息不被納入本新聞稿的引用。Clearmind 對第三方網站的內容不承擔責任。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU5UVTRPQ00zTXpZeE1ESTBJelV3TURBNE5qa3pOQT09?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU5UVTRPQ00zTXpZeE1ESTBJelV3TURBNE5qa3pOQT09"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MzhkYWVjNjEtOWU4OS00ZGRhLTgyNTAtYjIzOWQzZjNkMjMyLTUwMDA4NjkzNC0yMDI2LTAxLTE0LWVu/tiny/Clearmind-Medicine-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MzhkYWVjNjEtOWU4OS00ZGRhLTgyNTAtYjIzOWQzZjNkMjMyLTUwMDA4NjkzNC0yMDI2LTAxLTE0LWVu/tiny/Clearmind-Medicine-Inc-.png"/></p>

CMND

<p>Clearmind Medicine Inc. 已成功完成其 CMND-100（用於治療酒精使用障礙（AUD）的藥物候選者）第一/二期臨牀試驗第二組所有患者的治療。該試驗包括來自知名臨牀機構的六名患者，繼第一組的積極結果之後進行。首席執行官 Dr. Adi Zuloff-Shani 對進展表示滿意，並強調了 CMND-100 作為 AUD 創新療法的潛力。該組的初步結果預計很快會公佈</p>

<p>Vancouver, Canada, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the &#34;Company&#34;), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the successful completion of treatment for all patients in the second cohort of its ongoing FDA-approved Phase I/IIa clinical trial evaluating CMND-100, the Company’s proprietary MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD).</p>
<div class="lb-trans"><p>加拿大温哥華，2026 年 1 月 14 日（GLOBE NEWSWIRE）——Clearmind Medicine Inc.（納斯達克：CMND），（法蘭克福證券交易所：CWY0）（“Clearmind” 或 “公司”）是一家臨牀階段的生物技術公司，專注於發現和開發新型神經可塑素衍生的治療藥物，以解決主要的未得到充分治療的健康問題。今天，公司宣佈其正在進行的 FDA 批准的 I/IIa 期臨牀試驗的第二組所有患者的治療已成功完成，該試驗評估了 CMND-100，即公司自主研發的基於 MEAI 的口服藥物候選者，用於治療酒精使用障礙（AUD）。</p>
</div><p>The second cohort, consisting of six patients recruited across premier clinical sites, including Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center, has now fully completed the treatment per protocol. This milestone builds on the positive results from the first cohort, which demonstrated a favorable safety profile and preliminary efficacy signals, including reduced cravings and withdrawal symptoms.</p>
<div class="lb-trans"><p>第二組由六名患者組成，這些患者來自包括約翰霍普金斯大學、特拉維夫索拉斯基醫療中心和哈達薩醫療中心在內的頂級臨牀機構，現已按照協議完全完成治療。這個里程碑建立在第一組的積極結果之上，第一組顯示出良好的安全性特徵和初步的療效信號，包括減少渴求和戒斷症狀。</p>
</div><p>“We are pleased to announce the successful completion of treatment in the second cohort, within a month after receiving DSMB approval to continue enrollment, marking continued steady progress in our multinational Phase I/IIa trial,” said Dr. Adi Zuloff-Shani, Chief Executive Officer of Clearmind Medicine. “This achievement reflects the dedication of our clinical sites and the strong interest in CMND-100 as a potential innovative therapy for AUD, a condition with significant unmet medical needs. We look forward to upcoming data readouts and advancing toward subsequent cohorts.”</p>
<div class="lb-trans"><p>“我們很高興地宣佈第二組的治療成功完成，這在獲得 DSMB 批准繼續招募後一個月內實現，標誌着我們跨國 I/IIa 期試驗的持續穩定進展，” Clearmind Medicine 首席執行官 Adi Zuloff-Shani 博士表示。“這一成就反映了我們臨牀機構的奉獻精神以及對 CMND-100 作為 AUD 潛在創新療法的強烈興趣，這是一種具有顯著未滿足醫療需求的疾病。我們期待即將發佈的數據，並向後續組別推進。”</p>
</div><p>The Phase I/IIa trial is a multinational, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in patients with moderate to severe AUD. Topline results from the second cohort are anticipated in the coming months.</p>
<div class="lb-trans"><p>I/IIa 期試驗是一項跨國、多中心研究，旨在評估 CMND-100 在中度至重度 AUD 患者中的安全性、耐受性、藥代動力學和初步療效。第二組的頂線結果預計將在未來幾個月內公佈。</p>
</div><p><strong>About Clearmind Medicine Inc.</strong></p>
<div class="lb-trans"><p><strong>關於 Clearmind Medicine Inc.</strong></p>
</div><p>Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.</p>
<div class="lb-trans"><p>Clearmind 是一家臨牀階段的迷幻藥物生物技術公司，專注於發現和開發新型迷幻藥衍生的治療藥物，以解決廣泛且未得到充分服務的健康問題，包括酒精使用障礙。其主要目標是研究和開發基於迷幻藥的化合物，並嘗試將其商業化為受監管的藥物、食品或補充劑。</p>
</div><p>The Company’s intellectual portfolio currently consists of nineteen patent families, including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.</p>
<div class="lb-trans"><p>公司的知識產權組合目前包括十九個專利系列，其中包括 31 項已授予的專利。公司打算在必要時為其化合物申請更多專利，並將保持機會主義，收購更多知識產權以擴展其組合。</p>
</div><p>Shares of Clearmind are listed for trading on Nasdaq under the symbol &#34;CMND&#34; and the Frankfurt Stock Exchange under the symbol “CWY0.”</p>
<div class="lb-trans"><p>Clearmind 的股票在納斯達克以 “CMND” 符號交易，在法蘭克福證券交易所以 “CWY0” 符號交易。</p>
</div><p>For further information, visit: https://www.clearmindmedicine.com or contact:</p>
<div class="lb-trans"><p>欲瞭解更多信息，請訪問：https://www.clearmindmedicine.com 或聯繫：</p>
</div><p>Investor Relations</p>
<div class="lb-trans"><p>投資者關係</p>
</div><p>invest@clearmindmedicine.com</p>
<div class="lb-trans"><p>invest@clearmindmedicine.com</p>
</div><p>Telephone: (604) 260-1566</p>
<div class="lb-trans"><p>電話：（604）260-1566</p>
</div><p>US: CMND@crescendo-ir.com</p>
<div class="lb-trans"><p>美國：CMND@crescendo-ir.com</p>
</div><p>General Inquiries</p>
<div class="lb-trans"><p>一般諮詢</p>
</div><p>Info@Clearmindmedicine.com</p>
<div class="lb-trans"><p>Info@Clearmindmedicine.com</p>
</div><p>www.Clearmindmedicine.com</p>
<div class="lb-trans"><p>www.Clearmindmedicine.com</p>
</div><p><strong>Forward-Looking Statements:</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明：</strong></p>
</div><p>This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses progress in our multinational Phase I/IIa trial, interest in CMND-100 as a potential innovative therapy for AUD and advancing toward subsequent cohorts. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2024 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.</p>
<div class="lb-trans"><p>本新聞稿包含《私人證券訴訟改革法案》和其他證券法意義上的 “前瞻性聲明”。諸如 “預計”、“預期”、“打算”、“計劃”、“相信”、“尋求”、“估計” 等詞語或類似表達或變體旨在識別前瞻性聲明。例如，公司在討論我們跨國 I/IIa 期試驗的進展、對 CMND-100 作為 AUD 潛在創新療法的興趣以及向後續組別推進時使用了前瞻性聲明。前瞻性聲明不是歷史事實，基於管理層當前的期望、信念和預測，許多預測本質上是不確定的。這些期望、信念和預測是以誠信表達的。然而，無法保證管理層的期望、信念和預測將會實現，實際結果可能與前瞻性聲明中所表達或暗示的結果有重大差異。前瞻性聲明受到風險和不確定性的影響，這可能導致實際表現或結果與前瞻性聲明中所表達的有重大差異。有關影響公司的風險和不確定性的更詳細描述，請參考公司不時向證券交易委員會（“SEC”）提交的報告，包括但不限於公司截至 2024 年 10 月 31 日的財政年度的 20-F 表格年報中詳細列出的風險。前瞻性聲明僅在聲明發布之日有效。公司不承擔更新前瞻性聲明以反映實際結果、後續事件或情況、假設變化或影響前瞻性信息的其他因素的義務，除非適用的證券法要求。如果公司更新一項或多項前瞻性聲明，不應推斷公司將就此或其他前瞻性聲明進行額外更新。提供的參考和鏈接到網站僅為方便，網站上包含的信息不被納入本新聞稿的引用。Clearmind 對第三方網站的內容不承擔責任。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU5UVTRPQ00zTXpZeE1ESTBJelV3TURBNE5qa3pOQT09" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYyNTU4OCM3MzYxMDI0IzUwMDA4NjkzNA=="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MzhkYWVjNjEtOWU4OS00ZGRhLTgyNTAtYjIzOWQzZjNkMjMyLTUwMDA4NjkzNC0yMDI2LTAxLTE0LWVu/tiny/Clearmind-Medicine-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/MzhkYWVjNjEtOWU4OS00ZGRhLTgyNTAtYjIzOWQzZjNkMjMyLTUwMDA4NjkzNC0yMDI2LTAxLTE0LWVu/tiny/Clearmind-Medicine-Inc-.png"/></p>

Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial for CMND-100 | CMND Stock News

Clearmind Medicine 宣佈成功完成正在進行的 CMND-100 I/IIa 期臨牀試驗中第二組所有患者的治療 | CMND 股票新聞